{
    "version": "2025-01-09-base",
    "documents": [
        {
            "sentences": [
                {
                    "generated_prob": 0.933675229549408,
                    "sentence": "By Thomas CueniIn Geneva next week the World Health Organization is continuing discussions on how to respond to future pandemics.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.950408399105072,
                    "sentence": "It is critical in such planning to understand the roles played by both public and private financing in the historic response to COVID-19(https://financialpost.com/tag/covid-19/).A recent study(https://www.bmj.com/content/380/bmj-2022-073747) calculates that of the estimated $US31.9 billion of U.S. public financing for mRNA COVID-19 vaccines, just seven per cent ($US2.2 billion) supported R&;D and clinical trials of the Moderna vaccine between 2020 and 2022.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.938592791557312,
                    "sentence": "The lion's share of public funding, 92 per cent, was used to secure a guarantee for two billion vaccine doses, provided the mRNA COVID-19 vaccines proved effective.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.951152503490448,
                    "sentence": "Similarly, the U.K.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.964766263961792,
                    "sentence": "Vaccine Taskforce paid $US1.2 billion (£900 million) to secure 400 million vaccine doses.This snapshot misses the fact that Moderna and BioNTech had been burning money for years to develop their mRNA platforms and, even so, risked all on developing a COVID-19 vaccine before they had secured any public money.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.9677993059158325,
                    "sentence": "In 2020, private investors were first in line to shoulder the risk.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.9600517749786377,
                    "sentence": "Morgan Stanley raised $1.3 billion for Moderna to help build its vaccine supply capacity from scratch.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.9841265082359314,
                    "sentence": "A lifeline for BioNTech was $US14.3 million invested in Project Lightspeed by the Strüngmann brothers.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.9587665796279907,
                    "sentence": "Later Pfizer advanced 50 per cent of development costs from its $US2-billion COVID-19 war chest.The combined efforts of public and private funding contributed not only to developing two highly effective mRNA COVID-19 vaccines at record speed but also to scaling up their production at risk, enabling a rapid rollout.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.8529900908470154,
                    "sentence": "This built on significant investments in the decade before the pandemic.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.8996649980545044,
                    "sentence": "Both Moderna and BioNTech's mRNA platforms were heavily bankrolled by investors, high net-worth individuals and big pharma, with very little public funding.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.9508078694343567,
                    "sentence": "Moderna secured $US3.8 billion at risk to develop its mRNA platform.To put all this in perspective, in 2013 Moderna secured $US240 million from a partnership with AstraZeneca, with an additional $US25 million from the U.S. Department of Defense.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.9380781650543213,
                    "sentence": "BioNTech accumulated more than $US400 million of debts but nevertheless raised around $US720 million from private financing between 2017 and 2019.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.8347312211990356,
                    "sentence": "Public and private financing helped shoulder the risk that led to a way out of the pandemic, bringing a significant return on investment given the loss of societal and economic activity during the pandemic.Today, mRNA COVID-19 vaccines are seen as game-changers.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.7549983859062195,
                    "sentence": "But there was no guarantee the technology would work, so the importance of the achievement should not be underestimated.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.8441215753555298,
                    "sentence": "The three largest innovative vaccine companies (Sanofi, GSK, and MSD) attempted but ultimately failed to develop a COVID-19 vaccine in 2021.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.6991439461708069,
                    "sentence": "Some gave up altogether or didn't succeed until the end of 2022, by which time over 130 COVID-19 vaccines were in clinical trials.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.6945854425430298,
                    "sentence": "That companies are continuing R&;D on COVID vaccines even today is due to a strong and competitive innovation ecosystem making use of both private and public investment support.The proposed AI pause: Artificial intelligence meets human idiocy(https://financialpost.com/opinion/proposed-ai-pause-artificial-intelligence-meets-human-idiocy)Share buybacks harm no one.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.03175567835569382,
                    "sentence": "Let's not tax them(https://financialpost.com/opinion/share-buybacks-harm-no-one-dont-tax-them)Budget 2023 was a failed opportunity to address poor productivity(https://financialpost.com/opinion/joe-oliver-freeland-channels-edith-piaf-and-an-unlikely-predecessor)To prepare for Disease X by developing countermeasures even faster and to slash even the COVID-19 vaccines' record-breaking 326 days to as low as 100 days, the elements that worked well during this pandemic must be preserved.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.021176230162382126,
                    "sentence": "Unimpeded and timely access to emerging pathogens is key, but so is nurturing a proven R&;D ecosystem, supported by a reliable intellectual property framework, which encourages investors of all kinds to invest in the development of new treatments and vaccines.What did not work but really matters for future pandemics is fair access to vaccines.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.029142480343580246,
                    "sentence": "We need a social contract of the sort proposed by biotechs, developing-world manufacturers and big pharma, which would reserve an allocation of real-time production of vaccines and treatments for priority populations in lower-income countries and prescribe measures to make them both available and affordable.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.02732216753065586,
                    "sentence": "In their discussions in Geneva, WHO negotiators need to prioritize concrete practical measures as they draw up an accord on future pandemics.Thomas Cueni is director general of the International Federation of Pharmaceutical Manufacturers and Associations.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.005488230846822262,
                    "sentence": "!",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                },
                {
                    "generated_prob": 0.015847180038690567,
                    "sentence": "@COPYRIGHT=© 2023 Postmedia Network Inc. All rights reserved.",
                    "perplexity": 0,
                    "highlight_sentence_for_ai": false
                }
            ],
            "paragraphs": [
                {
                    "start_sentence_index": 0,
                    "num_sentences": 24,
                    "completely_generated_prob": 0.004689955524251948
                }
            ],
            "completely_generated_prob": 0.49770307481643766,
            "class_probabilities": {
                "human": 0.5021818426438073,
                "ai": 0.49770307481643766,
                "mixed": 0.00011508253975490195
            },
            "average_generated_prob": 0,
            "predicted_class": "human",
            "confidence_score": 0.5021818426438073,
            "confidence_category": "low",
            "confidence_scores_raw": {
                "identity": {
                    "ai": 0.49770307481643766,
                    "human": 0.5021818426438073,
                    "mixed": 0.00011508253975490195
                }
            },
            "confidence_thresholds_raw": {
                "identity": {
                    "ai": {
                        "reject": 0.65,
                        "low": 0.75,
                        "medium": 0.92
                    },
                    "human": {
                        "reject": 0.7,
                        "low": 0.82,
                        "medium": 0.92
                    },
                    "mixed": {
                        "reject": 0.7,
                        "low": 0.8,
                        "medium": 0.88
                    }
                }
            },
            "overall_burstiness": 0,
            "writing_stats": {},
            "subclass": {
                "ai": {},
                "human": {},
                "mixed": {}
            },
            "result_message": "Our detector is highly uncertain about this document. The writing style and content are not particularly AI-like.",
            "document_classification": "HUMAN_ONLY",
            "version": "2025-01-09-base",
            "language": "en",
            "inputText": "By Thomas CueniIn Geneva next week the World Health Organization is continuing discussions on how to respond to future pandemics. It is critical in such planning to understand the roles played by both public and private financing in the historic response to COVID-19(https://financialpost.com/tag/covid-19/).A recent study(https://www.bmj.com/content/380/bmj-2022-073747) calculates that of the estimated $US31.9 billion of U.S. public financing for mRNA COVID-19 vaccines, just seven per cent ($US2.2 billion) supported R&;D and clinical trials of the Moderna vaccine between 2020 and 2022. The lion's share of public funding, 92 per cent, was used to secure a guarantee for two billion vaccine doses, provided the mRNA COVID-19 vaccines proved effective. Similarly, the U.K. Vaccine Taskforce paid $US1.2 billion (£900 million) to secure 400 million vaccine doses.This snapshot misses the fact that Moderna and BioNTech had been burning money for years to develop their mRNA platforms and, even so, risked all on developing a COVID-19 vaccine before they had secured any public money. In 2020, private investors were first in line to shoulder the risk. Morgan Stanley raised $1.3 billion for Moderna to help build its vaccine supply capacity from scratch. A lifeline for BioNTech was $US14.3 million invested in Project Lightspeed by the Strüngmann brothers. Later Pfizer advanced 50 per cent of development costs from its $US2-billion COVID-19 war chest.The combined efforts of public and private funding contributed not only to developing two highly effective mRNA COVID-19 vaccines at record speed but also to scaling up their production at risk, enabling a rapid rollout. This built on significant investments in the decade before the pandemic. Both Moderna and BioNTech's mRNA platforms were heavily bankrolled by investors, high net-worth individuals and big pharma, with very little public funding. Moderna secured $US3.8 billion at risk to develop its mRNA platform.To put all this in perspective, in 2013 Moderna secured $US240 million from a partnership with AstraZeneca, with an additional $US25 million from the U.S. Department of Defense. BioNTech accumulated more than $US400 million of debts but nevertheless raised around $US720 million from private financing between 2017 and 2019. Public and private financing helped shoulder the risk that led to a way out of the pandemic, bringing a significant return on investment given the loss of societal and economic activity during the pandemic.Today, mRNA COVID-19 vaccines are seen as game-changers. But there was no guarantee the technology would work, so the importance of the achievement should not be underestimated. The three largest innovative vaccine companies (Sanofi, GSK, and MSD) attempted but ultimately failed to develop a COVID-19 vaccine in 2021. Some gave up altogether or didn't succeed until the end of 2022, by which time over 130 COVID-19 vaccines were in clinical trials. That companies are continuing R&;D on COVID vaccines even today is due to a strong and competitive innovation ecosystem making use of both private and public investment support.The proposed AI pause: Artificial intelligence meets human idiocy(https://financialpost.com/opinion/proposed-ai-pause-artificial-intelligence-meets-human-idiocy)Share buybacks harm no one. Let's not tax them(https://financialpost.com/opinion/share-buybacks-harm-no-one-dont-tax-them)Budget 2023 was a failed opportunity to address poor productivity(https://financialpost.com/opinion/joe-oliver-freeland-channels-edith-piaf-and-an-unlikely-predecessor)To prepare for Disease X by developing countermeasures even faster and to slash even the COVID-19 vaccines' record-breaking 326 days to as low as 100 days, the elements that worked well during this pandemic must be preserved. Unimpeded and timely access to emerging pathogens is key, but so is nurturing a proven R&;D ecosystem, supported by a reliable intellectual property framework, which encourages investors of all kinds to invest in the development of new treatments and vaccines.What did not work but really matters for future pandemics is fair access to vaccines. We need a social contract of the sort proposed by biotechs, developing-world manufacturers and big pharma, which would reserve an allocation of real-time production of vaccines and treatments for priority populations in lower-income countries and prescribe measures to make them both available and affordable. In their discussions in Geneva, WHO negotiators need to prioritize concrete practical measures as they draw up an accord on future pandemics.Thomas Cueni is director general of the International Federation of Pharmaceutical Manufacturers and Associations. !@COPYRIGHT=© 2023 Postmedia Network Inc. All rights reserved."
        }
    ]
}